DE69820419D1 - Klonierung und verwendung des lsr-rezeptors - Google Patents

Klonierung und verwendung des lsr-rezeptors

Info

Publication number
DE69820419D1
DE69820419D1 DE69820419T DE69820419T DE69820419D1 DE 69820419 D1 DE69820419 D1 DE 69820419D1 DE 69820419 T DE69820419 T DE 69820419T DE 69820419 T DE69820419 T DE 69820419T DE 69820419 D1 DE69820419 D1 DE 69820419D1
Authority
DE
Germany
Prior art keywords
lsr
purified
cloning
ffa
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69820419T
Other languages
English (en)
Other versions
DE69820419T2 (de
Inventor
Bernard Bihain
Lydie Bougueleret
Frances Yen-Potin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Biodevelopment SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9710088A external-priority patent/FR2767136B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Genset SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of DE69820419D1 publication Critical patent/DE69820419D1/de
Application granted granted Critical
Publication of DE69820419T2 publication Critical patent/DE69820419T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69820419T 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors Expired - Lifetime DE69820419T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9710088A FR2767136B1 (fr) 1997-08-06 1997-08-06 Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR9710088 1997-08-06
FR9805032A FR2767135B1 (fr) 1997-08-06 1998-04-22 Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
FR9805032 1998-04-22
PCT/IB1998/001257 WO1999007737A2 (fr) 1997-08-06 1998-08-06 Recepteur lsr, clonage et applications

Publications (2)

Publication Number Publication Date
DE69820419D1 true DE69820419D1 (de) 2004-01-22
DE69820419T2 DE69820419T2 (de) 2004-11-25

Family

ID=26233732

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69820419T Expired - Lifetime DE69820419T2 (de) 1997-08-06 1998-08-06 Klonierung und verwendung des lsr-rezeptors
DE69838720T Expired - Lifetime DE69838720T2 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel
DE69841186T Expired - Lifetime DE69841186D1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende Medikamente

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69838720T Expired - Lifetime DE69838720T2 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende arzneimittel
DE69841186T Expired - Lifetime DE69841186D1 (de) 1997-08-06 1998-08-06 Lipoprotein-regulierende Medikamente

Country Status (13)

Country Link
US (8) US6635431B1 (de)
EP (4) EP0964870B1 (de)
JP (3) JP2001512746A (de)
AT (3) ATE256146T1 (de)
AU (2) AU754942B2 (de)
CA (2) CA2274302A1 (de)
CY (1) CY1107808T1 (de)
DE (3) DE69820419T2 (de)
DK (2) DK1003783T3 (de)
ES (2) ES2296339T3 (de)
FR (1) FR2767135B1 (de)
PT (2) PT1003783E (de)
WO (2) WO1999007736A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
AU772243B2 (en) 1998-11-04 2004-04-22 Genset Genomic and complete cDNA sequences of human adipocyte-specific APM1 and biallelic markers thereof
AU767378B2 (en) * 1999-02-10 2003-11-06 Genset Polymorphic markers of the LSR gene
CA2370609A1 (en) * 1999-04-20 2000-10-26 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp3
WO2000063376A1 (en) * 1999-04-20 2000-10-26 Zymogenetics, Inc. Adipocyte complement related protein homolog zacrp2
CA2388417A1 (en) 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001032868A1 (en) * 1999-11-04 2001-05-10 Genset Apm1 biallelic markers and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en) * 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) * 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) * 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
ATE405655T1 (de) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa Obg3 globularekopf und seine verwendungen zur reduzierung des körpersgewichtes
IL153200A0 (en) * 2000-05-31 2003-07-06 Genset Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A gOBG3
JP2004504037A (ja) * 2000-07-18 2004-02-12 ジェンセット　ソシエテ　アノニム 肥満関連の二対立遺伝子マーカー地図
WO2002067979A1 (en) * 2001-02-26 2002-09-06 The University Of Sydney Method of improving the growth performance of an animal
CA2440144A1 (en) * 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
JP4547696B2 (ja) * 2001-06-07 2010-09-22 第一三共株式会社 肝硬変予防・治療剤
EP1414483A1 (de) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonisten und antagonisten von moxifin zur behandlung von stoffwechselerkrankungen
US7276342B2 (en) * 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003041738A1 (en) * 2001-11-15 2003-05-22 Genset S.A. Treatment of metabolic disorders with xitar agonists and antagonists
US7344843B2 (en) * 2001-11-29 2008-03-18 Serono Genetics Institute S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders
JP2005535561A (ja) * 2002-01-18 2005-11-24 プロテミックス コーポレイション リミティド アディポネクチンのグリコアイソフォームとその使用
US6852693B2 (en) 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
WO2003099319A1 (fr) * 2002-05-24 2003-12-04 Japan Science And Technology Agency Medicament preventif/curatif pour l'arteriosclerose
WO2003102027A1 (en) * 2002-05-31 2003-12-11 Serono Genetics Institute S.A. Homotrimeric extended obg3 globular head and uses thereof
DE602004022632D1 (de) * 2003-01-09 2009-10-01 Beth Israel Hospital Verwendung von adiponectin zur diagnose von krebs
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CA2590177A1 (en) * 2004-12-10 2006-06-15 Protemix Corporation Limited Glyponectin (glycosylated adiponectin) for the treatment of diseases and conditions
US7592423B2 (en) * 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US7678886B2 (en) * 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
WO2006074432A2 (en) * 2005-01-07 2006-07-13 Xencor Adiponectin variants
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7964557B2 (en) * 2005-03-28 2011-06-21 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
US20070054359A1 (en) * 2005-07-11 2007-03-08 Jonathan Zalevsky Rational Chemical Modification of Adiponectin Variants
JP2009502849A (ja) * 2005-07-29 2009-01-29 ラボラトワール セローノ ソシエテ アノニム 血栓症及び癌の治療、及び／又は予防のためのａｃｒｐ３０の使用
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en) * 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
KR101240875B1 (ko) * 2007-12-19 2013-03-08 일라이 릴리 앤드 캄파니 비만용 제약 요법에 대한 반응성을 예상하는 방법
JP5429736B2 (ja) * 2009-04-13 2014-02-26 国立大学法人神戸大学 タイトジャンクション調節剤
WO2012140627A1 (en) * 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2848291A1 (en) * 2012-06-21 2013-12-27 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
CN104004066B (zh) * 2013-02-26 2017-05-31 上海市第一人民医院 预防或抑制炎症反应和血管新生的小分子多肽及其应用
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
JP6372930B2 (ja) * 2013-12-27 2018-08-15 国立大学法人高知大学 悪性腫瘍の治療薬

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US67881A (en) * 1867-08-20 Geobge p
US77051A (en) * 1868-04-21 peters
US111500A (en) * 1871-01-31 Improvement in repeating fire-arms
US5543394A (en) * 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
NL9100132A (nl) * 1991-01-25 1992-08-17 Ingeny Bv Werkwijze voor het detecteren van dna sequentievariatie.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
FR2733762B1 (fr) 1995-05-02 1997-08-01 Genset Sa Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
US5869330A (en) 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
PT892849E (pt) 1996-01-23 2006-08-31 Indevus Pharmaceuticals Inc Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico
US6116126A (en) 1996-07-10 2000-09-12 Van Den Bulcke; Marc Method and machine for making profile pieces
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0941366A2 (de) 1996-11-06 1999-09-15 Whitehead Institute For Biomedical Research Biallelische marker
EP1002075B1 (de) * 1997-07-18 2006-05-24 ZymoGenetics, Inc. Adipozyten-spezifische protein homologe
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US6197930B1 (en) 1997-08-26 2001-03-06 Zymogenetics, Inc. Adipocyte-specific protein homologs
JP3538711B2 (ja) * 1997-10-29 2004-06-14 大塚製薬株式会社 平滑筋増殖抑制組成物、動脈硬化症診断方法及びそのキット
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US20030215836A1 (en) 2000-03-17 2003-11-20 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
EP1414483A1 (de) 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonisten und antagonisten von moxifin zur behandlung von stoffwechselerkrankungen
US7276342B2 (en) 2001-08-02 2007-10-02 Serono Genetics Institute S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
US7344843B2 (en) 2001-11-29 2008-03-18 Serono Genetics Institute S.A. Agonists and antagonists of prolixin for the treatment of metabolic disorders

Also Published As

Publication number Publication date
AU754942B2 (en) 2002-11-28
AU745607C (en) 2002-08-29
FR2767135B1 (fr) 2002-07-12
US20090263847A1 (en) 2009-10-22
DE69820419T2 (de) 2004-11-25
EP0964870B1 (de) 2003-12-10
EP1903057B1 (de) 2009-09-23
US20020165154A1 (en) 2002-11-07
DE69838720T2 (de) 2008-10-30
ES2296339T3 (es) 2008-04-16
US7919091B2 (en) 2011-04-05
US20080249009A1 (en) 2008-10-09
CY1107808T1 (el) 2013-06-19
WO1999007736A3 (en) 1999-05-20
EP1375516A3 (de) 2004-06-09
US6344441B1 (en) 2002-02-05
JP2001512746A (ja) 2001-08-28
WO1999007737A3 (fr) 1999-06-10
PT964870E (pt) 2004-02-27
DE69838720D1 (de) 2007-12-27
EP1003783A2 (de) 2000-05-31
AU745607B2 (en) 2002-03-21
ATE256146T1 (de) 2003-12-15
ATE443721T1 (de) 2009-10-15
EP1903057A2 (de) 2008-03-26
EP1375516A2 (de) 2004-01-02
EP0964870A2 (de) 1999-12-22
CA2274302A1 (fr) 1999-02-18
DE69841186D1 (de) 2009-11-05
WO1999007737A2 (fr) 1999-02-18
FR2767135A1 (fr) 1999-02-12
JP2001512492A (ja) 2001-08-21
US20110165166A1 (en) 2011-07-07
CA2298849A1 (en) 1999-02-18
US7220722B2 (en) 2007-05-22
US6635431B1 (en) 2003-10-21
JP2005143508A (ja) 2005-06-09
ATE378354T1 (de) 2007-11-15
PT1003783E (pt) 2007-12-06
JP3726969B2 (ja) 2005-12-14
US20040077051A1 (en) 2004-04-22
EP1003783B1 (de) 2007-11-14
AU8556498A (en) 1999-03-01
DK1003783T3 (da) 2008-01-02
DK0964870T3 (da) 2004-03-08
WO1999007736A2 (en) 1999-02-18
US20020151498A1 (en) 2002-10-17
EP1903057A3 (de) 2008-06-25
AU8556398A (en) 1999-03-01
US6946444B2 (en) 2005-09-20
US7291709B2 (en) 2007-11-06
ES2210786T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
DE69820419D1 (de) Klonierung und verwendung des lsr-rezeptors
ATE386126T1 (de) Verbesserte expressionsvektoren
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
ATE516354T1 (de) Apo-2-rezeptor
ATE25197T1 (de) Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
PT1169442E (pt) Polipeptidos segregados e transmembranares e acidos nucleicos que os codificam
NO944887L (no) Monoklonale antistoffer mot glykoprotein
DE59814354D1 (de) Zellvolumenregulierte humane Kinase h-sgk
ATE323764T1 (de) Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda
TR200000288T2 (tr) İnsülin C-peptidin rekombinan ekspresyonu.
ATE310810T1 (de) Polypeptid und dafür kodierendes nukeinsäure
WO2000012710A8 (en) Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
FR2697850B1 (fr) Nouveaux polypeptides ayant une activité de récepteur opioïde, acides nucléiques codant pour ces polypeptides et utilisations.
ATE335005T1 (de) Menschliches protein mit in vitro antiproliferativer aktivität.
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
ATE382059T1 (de) Neue humane androgenrezeptor-varianten
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
DK1241180T3 (da) Humant A33 antigen-lignende protein og nucleinsyrer, der koder for dette
PT1241185E (pt) Acido nucleico que e amplificado em tumores humanos e materiais e metodos relacionados
DK1249491T3 (da) Nucleinsyre, der opformeres i humane tumorer samt beslægtede materialer og fremgangsmåder
KR100515857B1 (en) PRO792 Polypeptides
DE69937756D1 (de) Menschliches Prostasin-ähnliches Protein und dafür kodierende Nukleinsäure
DE69827532D1 (de) Polypeptide und dafür kodierende Nukleinsäure
DK1241252T3 (da) Nucleinsyrer, der opformeres i tumorer samt relaterede materialer og fremgangsmåder
DE69939339D1 (de) Menschliches Synaptogyrin-ähnliches Protein und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition